Findings show a newly created drug can prevent runaway inflammation while still allowing the immune system to handle the virus, even when given late into infect
Duke University is leading a phase 1 trial of a universal flu vaccine that could provide longer and broader protection against seasonal and pandemic strains.
Ted Ross, Ph.D., will 'lead the development of novel vaccine platforms for a variety of infectious diseases, including influenza, HIV and COVID-19,' the Clinic said. He will be based at the Clinic's Florida Research and Innovation Center but will collaborate with researchers across the health system, including the Global Center for Pathogen & Human Health Research, which is part of the Cleveland Innovation District.